Biognosys is proud to announce the presentation of seven posters at this years’ virtual American Association for Cancer Research (AACR) Virtual Annual Meeting II (June 22-24, 2020).
The posters will highlight the utility of our powerful and versatile proteomics platform to provide integrated functional insights across the oncology drug discovery pipeline. From novel target discovery and validation through to profiling mechanisms of action and drug resistance in experimental models and biomarker discovery in clinical studies, check out all the posters below.
6404/28: “LiP-Quant, an Automated Chemoproteomic Approach to Identify Drug Targets in Complex Proteomes”
Presenter: Yuehan Feng
A collaboration with: ETH Zurich
4006/3: High-Resolution Limited Proteolysis (HR-LiP), a Novel Approach for Target Validation and Lead Compound Optimization
Presenter: Nigel Beaton
A collaboration with: Cedilla Therapeutics
Learn more about our Limited Proteolysis technology and how this approach allows us to identify the targets of small molecules:
927/10: “Deep Proteomic Profiling of CD4+ and CD8+ T Cell-depleted Tumor Models in PD-1 Treatment”
Presenter: Jan Muntel
A collaboration with: Crown Bioscience Inc.
4077/7: “Quantitative Proteomics Reveals Novel Immunomodulatory Pathways of Resistance to PARP Therapy”
Presenter: Kristina Beeler
A collaboration with: Cancer Research UK Cambridge Institute
5135/18: “Characterization of a Data-independent Acquisition Mass Spectrometry-based Workflow in the Plasma of NSCLC Subjects Reveals Host Immune Response Mechanisms”
Presenter: Kamil Sklodowski
5529/19: “Proteomic Profiling of FFPE Tumor Samples from Melanoma Subjects Treated with Anti-PD-1 Immunotherapy Identifies Proteins Associated with Response to Treatment”
Presenter: Kristina Beeler
A collaboration with: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
4266/20: “Proteomics for Precision Oncology: Profiling the Proteome of Matching Tumor and Adjacent Normal Tissue Using Data-independent Acquisition”
Presenter: Jakob Vowinckel
A collaboration with: Indivumed GmbH
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
